< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
31 - 40 of 63
- Molecular classification of IBD: diagnostic and therapeutic potentialFrom1 Jun 2018 → 1 Jun 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Quantitative profiling in applied gut microbiome researchFrom1 Jan 2018 → 31 Dec 2021Funding: FWO EOS
- The role of innate immunity in chronic intestinal inflammation and fibrosis: towards a cure for Inflammatory Bowel Disease?From1 Oct 2017 → 30 Sep 2021Funding: Fund Recuperation Fiscal Exemption
- Characterization of the transcriptome interactions between host and gut microbiota in health and diseaseFrom1 Oct 2017 → 30 Sep 2020Funding: FWO fellowships
- Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicalsFrom28 Aug 2017 → 31 Dec 2021Funding: FWO Strategic Basic Research Grant
- Targeting pro-resolving monocyte-derived macrophages as a novel therapeutic approach to favor remission and tissue repair in Inflammatory Bowel DiseaseFrom1 Jan 2017 → 31 Dec 2017Funding: Foreign foundations, funds with scientific view
- GENomic profilinG of ColitIS-associated Colorectal CANcerFrom1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
- Novel diagnostic and therapeutic approach to inflammatory bowel disease based on functional characterization of patients: the CrUCCial indexFrom1 Sep 2016 → 31 Aug 2022Funding: H2020 - Frontier Research (ERC)
- Therapeutic manipulation of the gut microbiome in inflammatory bowel diseaseFrom1 Aug 2016 → 9 Dec 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Fecal microbiota transplantation in patients with ulcerative colitis: fecal donor selection and interplay between intestinal microbiota, diet and host geneticsFrom1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 998
- Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study(2024)
Authors: Séverine Vermeire, Jeroen Raes, Noël Knops
- A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State(2024)
Authors: Tom Hillary, Maya Imbrechts, Thomas Vanassche, Maria Garmyn, Séverine Vermeire
- Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495 - Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension(2024)
Authors: Séverine Vermeire
Pages: 264 - 274 - Upgrading therapeutic ambitions and treatment outcomes(2024)
Authors: Séverine Vermeire
Pages: 84 - 85 - Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis(2024)
Authors: Séverine Vermeire
Pages: 393 - 408 - Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.(2024)
Authors: Séverine Vermeire
Pages: 54 - 64 - Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST(2024)
Authors: Séverine Vermeire
Pages: 175 - 185 - Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study(2024)
Authors: Jo Swinnen, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)